Abstract
Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.
Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Atrial Fibrillation – New Frontiers in Anticoagulation
Volume: 14 Issue: 1
Author(s): Ranji Thomas, Pierre Le Page and Andrew R.J. Mitchell
Affiliation:
Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.
Abstract: Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.
Export Options
About this article
Cite this article as:
Thomas Ranji, Page Le Pierre and Mitchell R.J. Andrew, Atrial Fibrillation – New Frontiers in Anticoagulation, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/1871529X1401140724094846
DOI https://dx.doi.org/10.2174/1871529X1401140724094846 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Device Therapies: New Indications and Future Directions
Current Cardiology Reviews The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity
Recent Patents on Cardiovascular Drug Discovery Periodontal Muco-Adhesive Formulations for the Treatment of Infectious Periodontal Diseases
Current Drug Delivery Effect of Gender on Main Clinical Chemistry Parameters in Aged Rats
Current Aging Science Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Current Options for the Pharmacotherapy of Obesity
Current Pharmaceutical Design Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?
Current Pharmaceutical Design Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia
Current Diabetes Reviews The Role of Amino Acids in the Modulation of Cardiac Metabolism During Ischemia and Heart Failure
Current Pharmaceutical Design Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design Substrate Binding and Kinetic Aspects of the Peroxidation Reaction of Four Polyunsaturated Fatty Acids in the COX Active Site of PGHS-1
Letters in Drug Design & Discovery